The adaptability of their targeting strategy, combining potential with current treatments, decreased overall toxicity, and precise targeting emphasizes the potential of CD44-targeted nanocarriers in the developing field of tailored therapy for NSCLC. The gene discussed is CD44; the disease is non-small cell lung carcinoma.